Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurological Development of Infants Exposed In-Utero to Tanezumab
NCT03031938Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tanezumab in osteoarthritis (OA), cancer pain and low back pain (LBP), sponsored by Pfizer. Primary endpoints: Occipital-frontal Head Circumference, Body Length and 8 more. Started Nov 2017; status: completed.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)cancer painlow back pain (LBP)
Beyond the preview
Go deeper on NCT03031938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031938.